Protalix Biotherapeutics Inc.

Plus: Pfizer’s Bourla posts message of support for Israel, and updates from AnaptysBio, AstronauTx, LimmaTech, GSK, Zhifei and Pixelgen

Plus: Ports now CSO at Cargo and updates from Protalix, Culture, 4D, DiaMedica, Likarda, Precise, Pixelgen and Oviva

Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more

Plus: Protalix/Chiesi therapy for Fabry wins EU approval, and updates from FibroGen, NGM and more

The decisions include Sarepta’s DMD candidate, which could become the first gene therapy to receive accelerated approval

February’s highlights include recommendations for Incyte’s Opzelura and Chiesi’s Elfabrio 

Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS

Comparing the profiles of up-and-coming therapies for Fabry disease

Three clinical and 11 preclinical candidates move beyond traditional enzyme replacement, aim for wider range of patients

Following last month’s 4-0 vote by the FTC to challenge Illumina’s pending $7.1 billion acquisition of Grail, the company announced that it filed an action in the General Court of